Oral Administration of Interleukin-10 and Anti-IL-1 Antibody Ameliorates Experimental Intestinal Inflammation

Gastroenterology Res. 2013 Aug;6(4):124-133. doi: 10.4021/gr556w. Epub 2013 Sep 9.

Abstract

Background: To elucidate the effects of a solution containing interleukin-10 and anti-IL-1 antibody in modulating experimental intestinal inflammation.

Methods: Colitis was induced in BALB/c mice by oral administration of dextran sodium sulphate; mice were then treated with interleukin-10 plus anti-IL-1 antibody at low dosage. Transepithelial electrical resistance of isolated mouse colon and colon lengths were evaluated. Cytokines concentrations in organocultures supernatants and plasma samples were evaluated by Enzyme-Linked Immuno Sorbent Assay. Tight junction proteins were evaluated by immunofluorescence, respectively.

Results: Oral administration of tested products restores intestinal barrier function during experimental intestinal inflammation in association with reduced levels of proinflammatory cytokines, increased interleukin-10 plasma concentrations and a tight junction architecture restoration.

Conclusion: Obtained results may contribute to modelling an interesting strategy for the treatment of patients with inflammatory bowel diseases.

Keywords: Anti-interleukin-1 alpha antibody; Interleukin-10; Intestinal bowel disease; Low doses; Tight-junctions.